scholarly article | Q13442814 |
P356 | DOI | 10.1007/BF00168921 |
P698 | PubMed publication ID | 8750922 |
P2093 | author name string | K Miyagawa | |
P Erne | |||
K Hermsmeyer | |||
M Eberhard | |||
P2860 | cites work | A new generation of Ca2+ indicators with greatly improved fluorescence properties | Q27860793 |
A set of programs for analysis of kinetic and equilibrium data. | Q34072934 | ||
Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts. Coupling to signaling systems and gene expression | Q34150245 | ||
Activation of the calcium release channel (ryanodine receptor) by heparin and other polyanions is calcium dependent. | Q34436186 | ||
Calcium-channel drugs: structure-function relationships and selectivity of action | Q36717230 | ||
Position of calcium antagonists in antihypertensive therapy | Q38152079 | ||
Pharmacokinetics of calcium antagonists | Q38199616 | ||
Inositol 1,4,5-trisphosphate releases Ca2+ from a Ca2+-transporting membrane vesicle fraction derived from human platelets. | Q41359997 | ||
The structurally novel Ca2+ channel blocker Ro 40-5967, which binds to the [3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts | Q41776362 | ||
Inositol 1,4,5-trisphosphate-induced calcium release in permeabilized platelets is coupled to hydrolysis of inositol 1,4,5-trisphosphate to inositol 1,4-bisphosphate | Q42288428 | ||
Inhibition of signal Ca2+ in dog coronary arterial vascular muscle cells by Ro 40-5967. | Q42497003 | ||
Metabolism of calcium antagonist Ro 40-5967: a case history of the use of diode-array u.v. spectroscopy and thermospray-mass spectrometry in the elucidation of a complex metabolic pathway | Q44797118 | ||
Potential-dependent inhibition of cardiac Ca2+ inward currents by Ro 40-5967 and verapamil: relation to negative inotropy | Q46438854 | ||
Resting state block and use independence of rat vascular muscle Ca++ channels by Ro 40-5967. | Q54031122 | ||
Reactive disulfides trigger Ca2+ release from sarcoplasmic reticulum via an oxidation reaction. | Q54102593 | ||
Ro 40–5967, in Contrast to Diltiazem, Does Not Reduce Left Ventricular Contractility in Rats with Chronic Myocardial Infarction | Q67689248 | ||
Lack of Negative Inotropic Effects of the New Calcium Antagonist Ro 40–5967 in Patients with Stable Angina Pectoris | Q67709727 | ||
Analysis of calcium binding to alpha-lactalbumin using a fluorescent calcium indicator | Q67812880 | ||
Increased negative inotropic effect of calcium-channel blockers in hypertrophied and failing rabbit heart | Q67898791 | ||
Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension | Q68045953 | ||
Antihypertensive properties of the novel calcium antagonist (1S,2S)-2-[2-[[3-(2-benzimidazolyl)propyl]methylamino] ethyl]-6- fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthyl methoxyacetate dihydrochloride in rat models of hypertension. Comparison wi | Q68823721 | ||
In vitro pharmacologic profile of Ro 40-5967, a novel Ca2+ channel blocker with potent vasodilator but weak inotropic action | Q69080302 | ||
Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: comparison with verapamil | Q69121839 | ||
Effects of sulfhydryl reagents and other inhibitors on Ca2+ transport and inositol trisphosphate-induced Ca2+ release from human platelet membranes | Q70305983 | ||
Selective inhibition of T-type Ca2+ channels by Ro 40-5967 | Q72018988 | ||
Cardiovascular Profile of Ro 40–5967, a New Nondihydropyridine Calcium Antagonist, Delineated in Isolated, Blood-Perfused Dog Hearts | Q72098789 | ||
Ca2+ channel actions of the non-dihydropyridine Ca2+ channel antagonist Ro 40-5967 in vascular muscle cells cultured from dog coronary and saphenous arteries | Q72104434 | ||
Measurement of receptor induced changes in intracellular free calcium in human platelets | Q72411558 | ||
Calcium and magnesium binding to rat parvalbumin | Q72498641 | ||
The Ca(++)-channel blocker Ro 40-5967 blocks differently T-type and L-type Ca++ channels | Q72897184 | ||
P433 | issue | 1 | |
P304 | page(s) | 94-101 | |
P577 | publication date | 1995-12-01 | |
P1433 | published in | Naunyn-Schmiedeberg's Archives of Pharmacology | Q1468251 |
P1476 | title | Effects of mibefradil on intracellular Ca2+ release in cultured rat cardiac fibroblasts and human platelets | |
P478 | volume | 353 |
Q40569159 | Induction of apoptosis by the calcium antagonist mibefradil correlates with depolarization of the membrane potential and decreased integrin expression in human lens epithelial cells |
Q41557934 | Prevention of lens epithelial cell growth in vitro using mibefradil-containing PLGA micro particles |
Q35645713 | T-type calcium channel antagonists, mibefradil and NNC-55-0396 inhibit cell proliferation and induce cell apoptosis in leukemia cell lines |
Q43762907 | Torsades de pointes caused by Mibefradil |
Search more.